AU2019312877B2 - Molecular assessment of TRBC usage - Google Patents

Molecular assessment of TRBC usage

Info

Publication number
AU2019312877B2
AU2019312877B2 AU2019312877A AU2019312877A AU2019312877B2 AU 2019312877 B2 AU2019312877 B2 AU 2019312877B2 AU 2019312877 A AU2019312877 A AU 2019312877A AU 2019312877 A AU2019312877 A AU 2019312877A AU 2019312877 B2 AU2019312877 B2 AU 2019312877B2
Authority
AU
Australia
Prior art keywords
seq
cell
gene
nucleotide sequence
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019312877A
Other languages
English (en)
Other versions
AU2019312877A1 (en
Inventor
Meggan Czapiga
Biao MA
Shimobi ONUOHA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Autolus Ltd
Original Assignee
Autolus Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autolus Ltd filed Critical Autolus Ltd
Publication of AU2019312877A1 publication Critical patent/AU2019312877A1/en
Application granted granted Critical
Publication of AU2019312877B2 publication Critical patent/AU2019312877B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2019312877A 2018-08-03 2019-07-18 Molecular assessment of TRBC usage Active AU2019312877B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1812650.8A GB201812650D0 (en) 2018-08-03 2018-08-03 Molecular assessment of TRBC usage
GB1812650.8 2018-08-03
PCT/GB2019/052011 WO2020025928A1 (en) 2018-08-03 2019-07-18 Molecular assessment of trbc usage

Publications (2)

Publication Number Publication Date
AU2019312877A1 AU2019312877A1 (en) 2021-01-28
AU2019312877B2 true AU2019312877B2 (en) 2025-12-18

Family

ID=63518375

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019312877A Active AU2019312877B2 (en) 2018-08-03 2019-07-18 Molecular assessment of TRBC usage

Country Status (8)

Country Link
US (1) US12241124B2 (https=)
EP (1) EP3830297A1 (https=)
JP (2) JP7606958B2 (https=)
CN (1) CN112534065B (https=)
AU (1) AU2019312877B2 (https=)
CA (1) CA3108000A1 (https=)
GB (1) GB201812650D0 (https=)
WO (1) WO2020025928A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11385233B2 (en) 2015-03-05 2022-07-12 Autolus Limited Methods of depleting malignant T-cells
US11982673B2 (en) 2014-03-05 2024-05-14 Autolus Limited Methods
GB201709203D0 (en) 2017-06-09 2017-07-26 Autolus Ltd Antigen-binding domain
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
CA3105448A1 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
GB201817172D0 (en) 2018-10-22 2018-12-05 Autolus Ltd Antibody
GB201817822D0 (en) 2018-10-31 2018-12-19 Autolus Ltd Binding domain
GB2599228B (en) 2019-02-21 2024-02-07 Marengo Therapeutics Inc Multifunctional molecules that bind to T cell related cancer cells and uses thereof
CN119039441A (zh) 2019-02-21 2024-11-29 马伦戈治疗公司 与nkp30结合的抗体分子及其用途
AU2020416273A1 (en) 2020-01-03 2022-07-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
WO2023236189A1 (zh) * 2022-06-10 2023-12-14 刘宗霖 利用非完整重组的t细胞受体核苷酸序列诊断t细胞淋巴瘤的方法及试剂盒

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102443624B (zh) * 2010-10-11 2014-12-10 遵义医学院 一种高通量同时测序多样本cdr3受体库的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103205420B (zh) 2012-01-13 2015-04-01 深圳华大基因科技有限公司 用于扩增T细胞受体β链CDR3编码序列的引物组合物及其用途
US11385233B2 (en) 2015-03-05 2022-07-12 Autolus Limited Methods of depleting malignant T-cells
DK3241561T3 (da) 2014-03-05 2025-06-30 Autolus Ltd Konjugeret antistof eller bispecifik t-celle-engager, som selektivt binder enten tcr-beta konstant region 1 (trbc1) eller trbc2
WO2016051205A1 (en) 2014-10-03 2016-04-07 Isis Innovation Limited Analysis of t-cell monotypia
EP3211003A1 (en) * 2016-02-24 2017-08-30 Institut Pasteur T cell receptors from the hiv-specific repertoire, means for their production and therapeutic uses thereof
CN110168105B (zh) 2016-12-09 2024-05-24 瑞泽恩制药公司 用于对t细胞受体进行测序的系统和方法及其用途
GB201709203D0 (en) 2017-06-09 2017-07-26 Autolus Ltd Antigen-binding domain
GB201800298D0 (en) 2018-01-09 2018-02-21 Autolus Ltd Method
GB201817172D0 (en) 2018-10-22 2018-12-05 Autolus Ltd Antibody
GB201817822D0 (en) 2018-10-31 2018-12-19 Autolus Ltd Binding domain

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102443624B (zh) * 2010-10-11 2014-12-10 遵义医学院 一种高通量同时测序多样本cdr3受体库的方法

Also Published As

Publication number Publication date
CA3108000A1 (en) 2020-02-06
US12241124B2 (en) 2025-03-04
JP7606958B2 (ja) 2024-12-26
JP2024023671A (ja) 2024-02-21
JP2021532792A (ja) 2021-12-02
CN112534065B (zh) 2025-08-26
CN112534065A (zh) 2021-03-19
US20220010377A1 (en) 2022-01-13
WO2020025928A1 (en) 2020-02-06
EP3830297A1 (en) 2021-06-09
GB201812650D0 (en) 2018-09-19
AU2019312877A1 (en) 2021-01-28

Similar Documents

Publication Publication Date Title
AU2019312877B2 (en) Molecular assessment of TRBC usage
AU2020213348B2 (en) Uniquely tagged rearranged adaptive immune receptor genes in a complex gene set
US8574832B2 (en) Methods for preparing sequencing libraries
AU2012325791B2 (en) Quantification of adaptive immune cell genomes in a complex mixture of cells
CA2706667C (en) Method for studying v(d)j combinatory diversity
KR101621643B1 (ko) 다중 pcr 반응에서 증폭 바이어스를 측정 및 교정하기 위한 조성물 및 방법
US20080166704A1 (en) Method for Quantitative Evaluation of a Rearrangement or a Targeted Genetic Recombination of an Individual and Uses Thereof
AU2021290268A1 (en) Immunorepertoire normality assessment method and its use
AU2009289809B2 (en) Screening methods for transfusion related acute lung injury (TRALI)
CN108368554B (zh) 弥漫性大b细胞淋巴瘤(dlbcl)亚型分型的方法
Salisu et al. Molecular markers and their Potentials in Animal Breeding and Genetics
JP2026062846A (ja) 核酸配列分析方法
KR101767644B1 (ko) 차등 발현 유전자를 이용한 돼지의 산자수 예측용 조성물 및 예측방법
US8158356B2 (en) Screening for the genetic defect causing tibial hemimelia in bovines
Bernardet et al. Sexing chicken embryos by real-time PCR using primers for the KCMF gene located on the W chromosome
JP7555272B2 (ja) 増幅方法
Brisco Quantifying Residual Leukemia by “Clone-Specific” Polymerase Chain Reaction
CN119020475A (zh) 一种基于三代测序白血病mrd检测系统及其试剂盒
WO2021202861A1 (en) Method of characterisation
Reid et al. Molecular testing for blood groups in transfusion medicine
Provan et al. Detection of minimal residual disease in hematological
WO2009003273A1 (en) Assessing tissue rejection
JP2010220586A (ja) 妊孕性診断方法、妊孕性診断キット、ポリヌクレオチド、ポリペプチド、及び抗体
PL235253B1 (pl) Sposób różnicowania, test diagnostyczny do różnicowania szczepów szczepionkowych od szczepów terenowych wirusa wścieklizny oraz zastosowanie testu diagnostycznego

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)